Mankind Pharma
Mankind Pharma, a prominent player in the Indian pharmaceutical industry, is headquartered in New Delhi, India. Founded in 1991, the company has established itself as a leader in the development, manufacturing, and marketing of a diverse range of pharmaceutical products, including prescription medications, over-the-counter drugs, and consumer healthcare items. With a strong focus on quality and innovation, Mankind Pharma has achieved significant milestones, including rapid expansion across major operational regions in India and beyond. The company is renowned for its unique formulations and commitment to affordable healthcare, positioning itself as a trusted name among healthcare professionals and consumers alike. Notable achievements include a robust market presence and recognition for its contributions to the pharmaceutical sector, making Mankind Pharma a key player in enhancing health outcomes across the region.
DitchCarbon Score
How does Mankind Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mankind Pharma's score of 33 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mankind Pharma's reported carbon emissions
In 2024, Mankind Pharma reported total carbon emissions of approximately 19,562,000 kg CO2e, comprising 5,831,000 kg CO2e from Scope 1 and 13,731,000 kg CO2e from Scope 2. This marks a significant reduction from the previous year's total emissions of about 43,596,000 kg CO2e in 2023, which included 14,519,000 kg CO2e from Scope 1 and 29,077,000 kg CO2e from Scope 2. The company has demonstrated a commitment to reducing its carbon footprint, achieving a notable decrease in emissions intensity per rupee of turnover, from 0.00054 in 2023 to 0.004805 in 2024. This indicates a proactive approach to sustainability within the pharmaceutical industry, although no specific reduction targets or climate pledges have been disclosed. Mankind Pharma's emissions data reflects its ongoing efforts to address climate change, focusing on reducing Scope 1 and Scope 2 emissions, which are directly linked to its operational activities. The absence of Scope 3 emissions data suggests that the company may still be developing strategies to manage indirect emissions associated with its value chain.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 15,753,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 28,074,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mankind Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
